Chemo Stability Chart LtoZ

BC CANCER AGENCY CHEMOTHERAPY PREPARATION AND STABILITY CHART
DRUG & STRENGTH

(Storage Prior to Use,
Manufacturer, Preservative
Status)
Lambrolizumab see
Pembrolizumab
Leucovorin
50 mg/5 mL
500 mg/50 mL
(Hospira)
(F)(PFL)
no preservative1
Reconstitute
With:
To Give:
Vial
Stability
Product
Product Stability
N/A
10 mg/mL1
5 mL vial: discard
unused portion2
syringe3
7 d F,3
48 h RT3,4
0.05-10 mg/mL
NS, D5W, Ringers,
Lactated Ringers,
D10W, D5NS1,2
24 h RT in NS, D5W,
Lactated Ringers,
Ringers1
50 mL vial: 8 h1
(e.g., 50-250 mL*)
BC Cancer Agency Chemotherapy Preparation and Stability Chart version 2.00

Activation Date: 2 March 2006
Revised Date: 1 June 2016
8 h RT in D10W, D5NS1
1/34
Special
Precautions/Notes

DRUG & STRENGTH
Status)
Leucovorin
50 mg/5 mL
500 mg/50 mL
(Teva)
(F)(PFL)
no preservative5
Reconstitute
With:
To Give:
Vial
Stability
Product
Product Stability
N/A
10 mg/mL1
discard unused
portion1
syringe
8 h6,7
0.06-1 mg/mL NS,

D5W, Ringers,
Lactated Ringers,
D10W, D10NS5
24 h RT in NS,
Lactated Ringers,
Ringers5
(e.g., 50-250 mL*)
12 h RT in D5W,
D10W5
6 h RT in D10NS5

2/34
Special
Precautions/Notes

DRUG & STRENGTH
Status)
Mechlorethamine
10 mg
(Ovation
Pharmaceuticals/Merck)
(RT,PFL)
no preservative8
Reconstitute
With:
To Give:
Vial
Stability
Product
Product Stability
do NOT use if
discoloured or water
droplets form in vial
before
reconstitution8
1 mg/mL8
use within 4 h of
reconstitution
RT9,7
syringe8
complete
administration within
4 h of reconstitution
RT7-9
100 mL NS8,10
complete
4 h of reconstitution
RT7,8,10
0.1 0.45 mg/mL in

NS only11
complete
60 min from time of
initial reconstitution at
RT9
10 mL SWI or NS8
record time of
reconstitution
Melphalan
50 mg
(GSK)
(RT)(PFL)
no preservative11
10mL supplied
diluent11
immediately after
adding diluent,
shake vigorously11
5 mg/mL11
2 h RT11
do NOT
refrigerate
(e.g., greater than 45

mg and less than or
equal to 110 mg in
250 mL NS)*
record time of
reconstitution

3/34
Special
Precautions/Notes

DRUG & STRENGTH
Status)
Mesna
1000 mg/10mL
(Fresenius Kabi)
(RT)
preservative12
Methotrexate
50 mg/2mL
500 mg/20mL
1 g/40mL
5 g/200mL
(Hospira)
(RT)(PFL)
no preservative13
Methotrexate
IT Injection13:
Only preservative free
methotrexate may be
administered by the
intrathecal route13
50 mg/2mL23
(Hospira)
(RT)(PFL)
no preservative13
Reconstitute
With:
To Give:
Vial
Stability
Product
Product Stability
N/A
100 mg/mL12
14 d F, RT7,12
Greater than or equal

to 1mg/mL12
48 h F, 24 h RT12
Special
Precautions/Notes
NS or D5W
N/A
N/A
25 mg/mL13
25 mg/mL13
50mg: discard
unused portion13
syringe
2 d F, RT9,14,15
500mg, 1 g, 5 g:
8 h F, RT13
0.42 mg/mL21
100 mL* NS, D5W
24 h RT21
high dose (e.g., 1-12

g/m2 as a single
dose)16-20: 1000 mL*
NS
24 h RT2,21,22
qs to 6 mL with
preservative free NS24
use within 4 h of initial

puncture9,7
discard unused
portion13

4/34
- for high-dose
regimens (e.g., 112 g/m2 as a single
dose)16-20: use
preservative-free
methotrexate9
- do not use for IT
injection
- auxiliary label25:
IT
- label to include
route in full (i.e.,
INTRATHECAL
injection) attached
to both syringe and
outer ziplock bag25

DRUG & STRENGTH
Status)
Methotrexate
50 mg/2mL
500 mg/20mL
(Hospira)
(RT)(PFL)
preservative13
Reconstitute
With:
To Give:
Vial
Stability
Product
Product Stability
N/A
25 mg/mL13
14 d F26,27
syringe
14 d F4,14
0.42 mg/mL21
24 h RT26
100 mL* NS, D5W13

Mitomycin
5 mg
20 mg
(Teva/Novopharm)
(RT)(PFL)
no preservative28
Mitomycin
5 mg
20 mg
(BMS)
(RT)(PFL)
no preservative29
SWI
5 mg: 10 mL
20 mg: 40 mL
shake well
0.5 mg/mL28
48 h F, RT7,28
14 d F, 48 h RT7,28
0.02-0.04 mg/mL28
NS, D5W, sodium
lactate28
3 h RT: D5W
12 h RT: NS
24 h RT: sodium
lactate28
syringe9
14 d F, 48 h RT9,30
0.020.04 mg/mL
12 h RT: NS
3h: D5W
24 h: sodium lactate29
**(PFL)28
28
SWI
5 mg: 10 mL
20 mg: 40 mL
syringe7
0.5 mg/mL29
48 h F, RT7,29
**(PFL)29
shake well29
NS, D5W, sodium

lactate29

5/34
Special
Precautions/Notes
- for high-dose
regimens (e.g., 112 g/m2 as a single
dose)16-20: use
preservative-free
methotrexate9
- do not use for IT
injection

DRUG & STRENGTH
Status)
mitoXANTRONE
20 mg/10 mL
25 mg/12.5 mL
(Hospira)
(RT)(PFL)
no preservative31
mitoXANTRONE
20 mg/10 mL
(Teva/Novopharm)
(RT)(PFL)
no preservative32
mitoXANTRONE
20 mg/10 mL
(Pharmaceutical
Partners of Canada)
(RT)
no preservative34
Reconstitute
With:
To Give:
Vial
Stability
Product
Product Stability
N/A
2 mg/mL31
discard unused
portion31
0.2-0.6 mg/mL31
NS: 24 h F, RT31
NS, D5W31
**(PFL)31

to *50 mL31
N/A
N/A
2 mg/mL32
2 mg/mL34
discard unused
portion32
discard unused
portion34

NS, D5W32
24 h RT32

to *50 mL32
**(PFL)33
NS, D5W34
24 h RT34

to 50 mL*34
6/34
Special
Precautions/Notes

DRUG & STRENGTH
Status)
Nivolumab
40 mg/4 mL
100 mg/10 mL
(BMS)
(F)(PFL)
do not shake
no preservative35
oBINutuzumab
1000 mg/40 mL
(Hoffman-La Roche)
(F)(PFL)**
do not shake
no preservative36
Reconstitute
With:
To Give:
Vial
Stability
Product
Product Stability
N/A
10 mg/mL35
discard unused
portion35
1-10 mg/mL35
complete
administration within 4
h RT or 24 h F35
- administer with a
0.2 to 1.2 micron
low protein binding
in-line filter35
- flush line with NS
or D5W following
infusion35
- discard if cloudy
or has pronounced
colour change
(should be clear to
pale yellow)35
24 h F, 48 h RT36,37
-once removed
from the fridge,
diluted product is
stable for an
additional 48 h
RT36,37
- do NOT shake36
- do NOT use
dextrose containing
solutions36
NS, D5W35
mix by gentle
inversion35
N/A
25 mg/mL36
discard unused
portion2
100 mg:
in 100 mL NS36
900 mg:
in 250 mL NS36
1000 mg:
in 250 mL NS36

7/34
Special
Precautions/Notes

DRUG & STRENGTH
Status)
Octreotide
50 mcg/mL
100 mcg/mL
500 mcg/mL
(Omega)
(F)(PFL)
no preservative38
Reconstitute
With:
To Give:
Vial
Stability
Product
Product Stability
N/A
50 mcg/mL
100 mcg/mL
500 mcg/mL38
Use within 4 h38
NS38
24 h RT38
200 mcg/mL38
15 d F38
multidose vial:
1000 mcg/5 mL
(Omega)
(F)(PFL)
preservative38
Octreotide
50 mcg/mL
100 mcg/mL
500 mcg/mL
(Teva/Novopharm)
(F)(PFL)
no preservative39
multidose vials:
1000 mcg/5 mL
(Teva/Novopharm)
(F)(PFL)
preservative39
Volume adjusted to
ensure a continuous
infusion of octreotide
at 25 mcg/hour38
NS38
24 h RT38
Volume adjusted to
ensure a continuous
infusion of octreotide
at 25 mcg/hour38
N/A
50 mcg/mL
100 mcg/mL
500 mcg/mL39
discard unused
portion39
sc syringe39
single use vials: use

within 4 h
multidose vials: use
within 14 d F27,39
200 mcg/mL39
14 d F27,39

infusion: NS39
single use or multidose

vials: 24 h RT39
8/34
Special
Precautions/Notes

DRUG & STRENGTH
Status)
Octreotide
(SANDOSTATIN)
1000 mcg/5 mL
(Novartis)
(F)(PFL)
preservative40
Octreotide
(SANDOSTATIN)
50 mcg/1 mL
100 mcg/1 mL
500 mcg/1 mL
(Novartis)
(F)(PFL)
no preservative40
Octreotide
(SANDOSTATIN LAR)
10 mg
20 mg
30 mg
(Novartis)
(F)(PFL)
no preservative41
Reconstitute
With:
To Give:
Vial
Stability
Product
Product Stability
N/A
200 mcg/mL40
discard unused
portion41
50200 mL NS9,42,43
24 h RT42
Special
Precautions/Notes
SC infusion: adjust
volume to ensure
infusion rate of 25
mcg/h42
N/A
50 mcg/mL
100 mcg/mL
500 mcg/mL40
discard unused
portion42
50-100 mL9,43
24 h RT42
NS42
SC infusion: adjust
volume to ensure
infusion rate of 25
mcg/h42
2 mL supplied
diluent
10 mg: 5 mg/mL
20 mg: 10 mg/mL
30 mg: 15 mg/mL42
discard unused
portion42
deep intragluteal
administration only42

reconstitution7,42
gently run 2 mL
down sides of the
vial; do NOT disturb
for 25 min, then
swirl moderately42
record time of
reconstitution

9/34
- do NOT shake

DRUG & STRENGTH
Status)
oFAtumumab
100 mg/ 5 mL
1000 mg/50 mL
(GlaxoSmithKline)
(F)(PFL)
no preservative44
Reconstitute
With:
To Give:
Vial
Stability
Product
Product Stability
N/A
20 mg/mL44
discard unused
portion2
1000 mL NS44
48 h RT44
or
alternatively, 2000 mg
doses may be
supplied in
2 x 500 mL NS44
withdraw volume
from bag equal to
volume of drug to be
added44

10/34
Special
Precautions/Notes
- administer with
0.2 micron low
protein binding inline filter44
- do NOT shake;
mix by slow
inversion to avoid
formation of foam44
- solution may
contain a small
quantity of drug
particles; do not
administer if
solution is cloudy
or discoloured44

DRUG & STRENGTH
Status)
Oxaliplatin
50 mg/10 mL
100 mg/20 mL
200 mg/40 mL
(sanofi-aventis)
(RT)(PFL)
no preservative45
Reconstitute
With:
To Give:
Vial
Stability
Product
Product Stability
N/A
5 mg/mL45
discard unused
portion45
0.2-1.3 mg/mL46
0.2-1.3 mg/mL:
14 d F, 48 h RT4,46,47
1.32 mg/mL45,46
250500 mL D5W45
1.3-2 mg/mL:
48 h F, 24 h RT45
Special
Precautions/Notes
- do NOT use
aluminumcontaining needle,
syringe or tubing45
do NOT use NS or
other chloridecontaining solution45
do NOT use
aluminum-containing
needle and syringe45
PACLitaxel
30 mg/5 mL
100 mg/16.7 mL
300 mg/50 mL
(Accord)
(RT)(PFL)
no preservative48
N/A
6 mg/ mL48
30 mg/5 mL or
100 mg/16.7 mL
vial:
48 h RT2,48
300 mg/50 mL
vial:
24 h RT48

0.3-1.2 mg/mL in NS,

D5W, D5NS, D5LR48
(e.g., 100-1000 mL)*
complete
27 h RT48
devices with spikes

(e.g., chemo
dispensing pins)
should not be used
with vials48
11/34
- use non-DEHP
bag and tubing with
0.22 micron in-line
filter48
- avoid excessive
shaking48

DRUG & STRENGTH
Status)
PACLitaxel
30 mg/5 mL
100 mg/16.7 mL
300 mg/50 mL
(Biolyse)
(RT)49
no preservative50
Reconstitute
With:
To Give:
Vial
Stability
Product
Product Stability
N/A
6 mg/mL50
48 h RT2,51

D5W50
(e.g., 100-1000 mL)*
complete
27 h RT50,52
0.1 mg/mL in NS53
44 h F, RT53
0.012-0.12 mg/mL in
NS54
16 h RT52
devices with spikes

(e.g., chemo
dispensing pins) may
be used with vials55

12/34
Special
Precautions/Notes
- use non-DEHP
bag and tubing with
in-line filter50

DRUG & STRENGTH
Status)
PACLitaxel
30 mg/5 mL
100 mg/16.7 mL
300 mg/50 mL
(BMS)
(RT)(PFL)
no preservative56
Reconstitute
With:
To Give:
Vial
Stability
Product
Product Stability
N/A
6 mg/mL56
30 mg/5 mL or
100 mg/16.7 mL
vial:
48 h RT27,56

D5W, D5NS, D5LR56
(e.g., 100-1000 mL)*
complete
27 h RT56
300 mg/50 mL
vial:
24 h RT56
0.1-1 mg/mL in NS,

D5W54
48 h F, RT54
Special
Precautions/Notes
- use non-DEHP
bag and tubing with
in-line filter56
devices with spikes

(e.g., chemo
dispensing pins)
should not be used
with vials56
PACLitaxel
30 mg/5 mL
100 mg/16.7 mL
150 mg/25 mL
300 mg/50 mL
(Hospira)
(RT)(PFL)
preservative57
N/A
6 mg/mL58
48 h RT2,58,59


D5W, D5NS, D5LR58
(e.g., 100-1000 mL)*
complete
27 h RT58
devices with spikes

(e.g., chemo
dispensing pins)
should not be used
with vials58
13/34
- use non-DEHP
bag and tubing with
in-line filter58

DRUG & STRENGTH
Status)
PACLitaxel,
nanoparticle, albuminbound (nab)
100 mg
(Celgene)
(RT)(PFL)
no preservative60
Reconstitute
With:
To Give:
Vial
Stability
Product
Product Stability
20 mL NS60
5 mg/mL60
use immediately
(RT) or
8 h F60
in empty sterile PVC,

non-PVC, or nonDEHP infusion bag60
48 h F plus an
additional 8 h RT61
- each vial contains

900 mg human
albumin60
- to prevent
foaming, do NOT
inject NS directly
onto the powder60
- some settling may
occur; use mild
agitation to
resuspend60
- discard if
precipitation
occurs60
- in-line filters are
not routinely
recommended60
0.060.36 mg/mL NS,

D5W62
24 h F followed by 24 h
RT (total 48 h)62
- do NOT mix with

calcium containing
solution (e.g.,
Ringers)62
- slowly direct
diluent against side
of vial (i.e., greater
than or equal to 1
min) during
reconstitution60
**(PFL)60
- let stand for

greater than or
equal to 5 min to wet
powder60
- gently swirl or
invert for greater
than or equal to 2
min60
Pamidronate
30 mg/10 mL
60 mg/10 mL
90 mg/10 mL
(Hospira)
(RT)
no preservative62
N/A
3 mg/mL
6 mg/mL
9 mg/mL62
discard unused
portion62

63
**(PFL)62
e.g., 250 mL* NS
14/34
Special
Precautions/Notes

DRUG & STRENGTH
Status)
Pamidronate
30 mg/10 mL
60 mg/10 mL
90 mg/10 mL
(Omega)
(RT)
no preservative64
Pamidronate
30 mg/10 mL
60 mg/10 mL
90 mg/10 mL
(Fresenius Kabi)
(RT)
no preservative65
Pamidronate
30 mg/10 mL
60mg/10 mL
90 mg/10 mL
(Sandoz Canada)
RT
no preservative66
Reconstitute
With:
To Give:
Vial
Stability
Product
Product Stability
N/A64
3 mg/mL
6 mg/mL
9 mg/mL64
discard unused
portion64
0.060.36 mg/mL NS,

D5W64
24 h F followed by 24 h
RT (total 48 h)64
e.g., 250 mL* NS63
**(PFL)64
3 mg/mL
6 mg/mL
9 mg/mL65
discard unused
portion65
NS; D5W65
24 h RT65
- do NOT mix with

calcium containing
solutions65
3 mg/mL
6 mg/mL
9 mg/mL66
discard unused
portion66,27
24 h RT66
- do NOT mix with

calcium containing
solution (e.g.,
Ringers)66
N/A65
N/A66
Less than or equal to

0.36 mg/mL65

NS; D5W66
15/34
Special
Precautions/Notes
- do NOT mix with

calcium containing
solution (e.g.,
Ringers)64

DRUG & STRENGTH
Status)
PANitumumab
100 mg/5 mL
200 mg/10 mL
400 mg/20 mL
(Amgen)
(F)(PFL)
do not shake
no preservative67
pegaspargase
(PEG-asparaginase)
(pegylated
asparaginase E. coli)
750 units/mL
(sigma tau)
(F)(PFL)
no preservative69
Reconstitute
With:
To Give:
Vial
Stability
Product
Product Stability
N/A
20 mg/mL67
discard unused
portion67
Less than or equal to

1000 mg: 100 mL
NS67
24 h F, 6 h RT67,68
- administer with
0.2 or 0.22 micron
low protein binding
in-line filter67
- solution may
contain particulates
which do not affect
product quality67
- do not administer
if discoloured67
IM:
maximum volume 2
mL; if greater than
2 mL use multiple
sites69
syringe:
discard at end of
day2,69
IV:
100 mL NS, D5W69
bag:
complete
48 h F69
- discard cloudy
solution69
- do not shake69
- do not use if
stored out of
refrigerator for
greater than 48 h69
- do not use if
previously frozen69
Greater than 1000mg:

150 mL NS67
1-10mg/mL67,68
N/A
750 units/mL69
discard unused
portion69
protect bag from direct

sunlight during
infusion69

16/34
Special
Precautions/Notes

DRUG & STRENGTH
Status)
Pembrolizumab
50 mg
(Merck)
(F)
no preservative70
Reconstitute
With:
To Give:
Vial
Stability
Product
Product Stability
Special
Precautions/Notes
2.3 mL SWI70
25 mg/mL70
6 h RT, 24 h F70
1-10 mg/mL NS70
6 h RT, 24 h F70
- use 0.2 to 5
micron in-line
filter70
- allow vials/bags
to come to RT prior
to use70
25 mg/mL71
24 h F, RT71
100 mL
preservative-free
NS71
24 h F, RT71
direct diluent against

side of vial during
reconstitution to
avoid foaming70
allow up to 5
minutes for bubbles
to clear70
do NOT shake70
Pemetrexed
100 mg
500 mg
(Eli Lilly)
(RT)
no preservative71
PERTuzumab
420 mg/14 mL
(Roche)
(F)(PFL)
no preservative73
100 mg: 4.2 mL

preservative-free NS
500 mg: 20 mL
preservative-free
NS71
N/A
do NOT mix with

calcium containing
solution (e.g.,
Ringers)72
30 mg/mL73
do NOT shake73
discard unused
portion273

250 mL NS only73
24 h F, RT73
mix by gentle
inversion to avoid
foaming73
17/34
- do NOT use
dextrose containing
solutions73

DRUG & STRENGTH
Status)
Porfimer
15 mg
75 mg
(Axcan)
(RT)(PFL)
no preservative74
Reconstitute
With:
To Give:
Vial
Stability
Product
Product Stability
15 mg: 6.6 mL D5W
2.5 mg/mL74
24 h F
syringe74

reconstitution7,75
**(PFL)74
75 mg: 31.8 mL
D5W74
**(PFL)74
Special
Precautions/Notes
- avoid contact with

skin and eyes;
protect exposed
area from light74
record time of
reconstitution
Raltitrexed
2 mg
(Hospira)
(F, RT)(PFL)
no preservative76
Ramucirumab
100 mg/10 mL
500 mg/50 mL
(Eli Lilly)
(F)(PFL)
(do not shake)
no preservative77
4 mL SWI76
0.5 mg/mL76
24 h F, RT76
50250 mL NS,
D5W76
24 h F, RT76
N/A
10 mg/mL77
discard unused
portion77
dilute to 250 mL final

volume with NS only77
4 h RT, 24 h F77

gently invert to mix77

do NOT shake77
18/34
- use 0.22 micron

filter77
- flush line with NS
following
administration77
- do NOT use
dextrose containing
solutions77

DRUG & STRENGTH
Status)
Reovirus Serotype 3
Dearing Strain
REOLYSIN
Dose (viral titre) in each
shipment may vary and
must be checked
closely
(Oncolytics Biotech)
(less than or equal to
-70 C)(PFL)
no preservative78
riTUXimab
100 mg/10 mL
500 mg/50 mL
(Roche)
(F)(PFL)
no preservative79
Reconstitute
With:
To Give:
Vial
Stability
Product
Product Stability
Special
Precautions/Notes
N/A78
dose (viral titre) in

each shipment
may vary and must
be checked
closely78
time from thawing

and dilution to
patient
administration
should be less
than 8 h; may be
extended to 24 h
if necessary78
250 mL NS78
complete
8 h of removal from
freezer; may be
extended to
24 h if necessary78
- auxiliary label:
biohazard2
refrigerate diluted
product until delivery to
treatment room78
thaw at room
temperature or in
fridge78
N/A
10 mg/mL79
discard unused
portion79

1-4 mg/mL NS,

D5W79
24 h F, 12 h RT80,81
(e.g., 250-500 mL)*
19/34
- once removed
from the fridge,
compounded
product is stable
for 12h RT80,81

DRUG & STRENGTH
Status)
Romidepsin
10 mg
(Celgene)
(RT)
no preservative82
Siltuximab
100 mg
400 mg
(Janssen)
(F)(PFL)
no preservative84
Reconstitute
With:
To Give:
Vial
Stability
Product
Product Stability
2 mL supplied
diluent82
5 mg/mL82
8 h RT82
500 mL NS, D5W,

Lactated Ringers82
24 h RT82
- reconstituted
solution will be
slightly viscous83
- NOTE: unlikely to
recover full 2 mL
from reconstituted
vial; expected
recovery volume
from each vial is
1.6 to 1.8 mL of
drug solution83
20 mg/mL84
2 h RT84
250 mL D5W84
complete
6 h RT 84
- use 0.2 micron inline filter84
inject slowly and

swirl gently to mix82
100 mg:
5.2 mL SWI84
400 mg:
20 mL SWI84
allow vial to come to
room temperature
prior to use (~30
minutes)84

volume by
withdrawing volume
from bag equal to
volume of drug to be
added84
gently swirl, do not

shake84

20/34
Special
Precautions/Notes
Streptozocin
1g
(Pfizer)
(F)(PFL)
no preservative85
Temozolomide
100 mg
(Schering)
(F)
do not dilute
do not shake
no preservative86
Temsirolimus
30 mg/1.2 mL
(Wyeth)
(F)(PFL)87,88
no preservative89
Teniposide
50 mg/5 mL
(BMS)
(RT)
preservative90
9.5mL NS, SWI,

D5W85
100 mg/mL85
48 h F,85 24 h RT
syringe85
48 h F, 24 h RT85
50-500 mL* NS,

D5W, SWI85
48 h F, 24 h RT85
41 mL SWI86
2.5 mg/mL86
14 h F, RT86
empty 250 mL PVC

bag86
14 h RT86
1.8 mL supplied
diluent87,88
10 mg/mL87,88
24 h RT87,88
250 mL NS87,88
complete
h87,88
- use non-DEHP
bag and tubing with
in-line filter87,88
N/A
10 mg/mL90
50 500 mL NS or
D5W for a final
concentration of 0.1-1
mg/mL90
0.1-0.4 mg/mL: 24 h
RT90
- do not refrigerate
- use non-DEHP
bag and tubing90
- do not use if
precipitates90,91
- excessive
agitation may
cause
precipitation90
**(PFL)87
discard unused
portion

1 mg/mL: complete
h of preparation RT90,91
21/34
Thiotepa
15 mg
(Bedford)
(F)(PFL)
no preservative92
1.5 mL SWI92
10 mg/mL92
8 h F92
filter through 0.22

micron filter92
diluents containing
preservatives should
NOT be used for
intrathecal
administration

reconstitution92,93
**(PFL)92,94
record time of
reconstitution
Thiotepa
IT injection:
15 mg
(Bedford)
(F)(PFL)
no preservative92
50 mL* NS92
10 mg/mL92
8 h F92
syringe: reconstituted
solution is hypotonic
and must be further
diluted with NS prior
to use92
(final concentration of
0.5-1 mg/ml is nearly
isotonic)95

reconstitution92,93
qs to 6 mL with
preservative free NS96

reconstitution92,93
**(PFL)92,94
**(PFL)92,94
1.5 mL SWI92
filter through 0.22
micron filter92
record time of
reconstitution
Thyrotropin alfa
1.1 mg
(Genzyme)
(F)(PFL)
no preservative97
1.2 mL SWI97
0.9 mg/mL97
24 h F97
syringe97
24 h F97
swirl contents97; do
not shake

- do not use if
precipitates or
remains opaque92
- do not use for IT
injection
22/34
- auxiliary label24:
IT
- label to include
route in full (i.e.,
INTRATHECAL
injection) attached
to both syringe and
outer ziplock bag24
- do not use if
precipitates or
remains opaque92
Tocilizumab
80 mg/4 mL
200mg/10 mL
400 mg/20 mL
(Genentech)
(F)(PFL)
no preservative98
Topotecan
4 mg
(Hospira)
(F)(PFL)
no preservative100
Topotecan
4 mg
(Mylan)
(RT)(PFL)
no preservative102
Topotecan
4 mg/4 mL
(Sandoz)
(F)(PFL)
no preservative103
N/A
20 mg/mL98
6 h30,98
100 mL NS
24h F,98
6 h RT99

volume by
withdrawing volume
of NS from 100 mL
bag equal to volume
of drug required for
dose prior to adding
drug98
N/A100
1 mg/mL100
discard unused
portion101
0.020.5 mg/mL100
24 h F, RT100
50-100 mL NS,
D5W101
4 mL SWI102
1 mg/mL102
24 h F, RT102
0.02 0.5 mg/mL102
24 h F, RT102
50-100 mL NS,
D5W102
N/A
1 mg/mL103
discard unused
portion103

0.02-0.5 mg/mL
24 h F103
50-100 mL NS,
D5W103
**(PFL)103
23/34
- to prevent
foaming: slowly
add drug to
infusion bag and
gently invert bag to
mix98
Trastuzumab
(HERCEPTIN)
440 mg
(Roche)
(F)
preservative104
Trastuzumab
Emtansine
(KADCYLA)
100 mg
160 mg
(Hoffmann-La Roche)
(F)(PFL)
no preservative105
20 mL supplied
BWI104
21 mg/mL104
14 d F2
24 h F, RT104
- do NOT shake104
24 h F105
- do not use if
reconstituted
solution contains
visible particulates
or is cloudy or
discolored105
- dextrose 5%
solutions cause
aggregation of the
protein; do not
dilute with dextrose
containing
solutions105
- use a 0.2 micron
in-line filter or 0.22
micron
polyethersulfane
(PES) filter to
administer
infusions prepared
in NS; filter is
optional for
solutions in 0.45%
NS105
Do NOT use dextrose

containing solutions104
swirl vial gently;

allow to stand
undisturbed for 5
min104
100 mg vial: 5 mL
SWI105
250 mL NS only104
20 mg/mL105
24 h F105
do NOT freeze105
160 mg vial: 8 mL
SWI105
250 mL NS or 0.45%
sodium chloride105
105
do NOT freeze105
do NOT shake
swirl gently until

completely
dissolved; do NOT
shake105

24/34
Treosulfan
1g
5g
(medac)
(RT)
no preservative106
pre-heat SWI to
30C (not higher)
shake vial carefully
before adding the
warmed SWI
1 g vial: 20 mL SWI,
while slightly
shaking vial and
syringe; continue
shaking the
reconstituted
solution for another
2 min106
5 g vial: 100 mL
SWI, while slightly
shaking vial and
syringe; continue
shaking the
reconstituted
solution for another
2 min106
50 mg/mL106
48 h RT7,106

undiluted107
48 h RT7,106
dilute with NS or D5W

in empty infusion bag
for final concentration
= 20 mg/mL106
25/34
- compatible with
polytetrafluoroethyl
ene filters106
- may require
vigorous shaking to
reconstitute106
vinBLAStine
10 mg/10 mL
(Hospira)
(F)(PFL)
no preservative108
vinBLAStine
10 mg/10 mL
(Teva)
(F)(PFL)
no preservative114
N/A
1 mg/mL108
discard unused
portion108
25-50 mL NS, D5W109
24 h F, RT110,111
- auxiliary label:
WARNING: FOR
INTRAVENOUS
USE ONLY
FATAL IF GIVEN
BY OTHER
ROUTES112,113
N/A
1 mg/mL114
discard unused
portion114
25-50 mL NS,
D5W109,115

puncture2
- auxiliary label:
WARNING: FOR
INTRAVENOUS
USE ONLY
FATAL IF GIVEN
BY OTHER
ROUTES112,113

26/34
vinCRIStine
2 mg/2 mL
5 mg/5 mL
(Hospira)
(F)(PFL)
no preservative116
vinCRIStine
1 mg/1 mL
2 mg/2 mL
5 mg/5 mL
(Teva)
(F)(PFL)
no preservative117
N/A
1 mg/mL116
8 h F, RT116
50 mL* NS, D5W116
24 h F, 6 h RT116
**(PFL)116
N/A
1 mg/mL117
8 h F, RT117

0.01-0.1 mg/mL NS or
D5W117
24 h F, RT117
25-50 mL NS, D5W118
27/34
- auxiliary label:
WARNING: FOR
INTRAVENOUS
USE ONLY
FATAL IF GIVEN
BY OTHER
ROUTES112,113
- for ULYEPOCHR
protocol, see entry
for EPOCHR
(3-in-1solution
containing
etoposide,
DOXOrubicin,
vinCRIStine)
- auxiliary label:
WARNING: FOR
INTRAVENOUS
USE ONLY
FATAL IF GIVEN
BY OTHER
ROUTES112,113
- for ULYEPOCHR
protocol, see entry
for EPOCHR
(3-in-1solution
containing
etoposide,
DOXOrubicin,
vinCRIStine)
Vinorelbine
10 mg/1 mL
50 mg/5 mL
(GSK)
(F)(PFL)
no preservative119
Vinorelbine
10 mg/1 mL
50 mg/5 mL
(Hospira)
(F)(PFL)
no preservative120
N/A
10 mg/mL119
discard unused
portion119
0.52.0 mg/mL119
24 h F, RT119
- auxiliary label:
WARNING: FOR
INTRAVENOUS
USE ONLY
FATAL IF GIVEN
BY OTHER
ROUTES112,113
24 h F, RT120
- auxiliary label:
WARNING: FOR
INTRAVENOUS
USE ONLY
FATAL IF GIVEN
BY OTHER
ROUTES112,113
50 mL* NS, D5W,

NS, D5NS,
Ringers, Ringers
Lactate119
N/A
10 mg/mL120
discard unused
portion120

0.52.0 mg/mL120
50 mL* NS, D5W,
NS, D5NS,
Ringers, Ringers
Lactate120
28/34
Vinorelbine
10 mg/1 mL
50 mg/5mL
(Fresenius Kabi)
(F)(PFL)
no preservative121
Vinorelbine
10 mg/1 mL
50 mg/5mL
(Pierre Fabre Pharma
Canada)
(F)(PFL)
no preservative122
N/A
10 mg/mL121
discard unused
portion121
0.5-2.0 mg/mL121
24 h F, RT121
- auxiliary label:
WARNING: FOR
INTRAVENOUS
USE ONLY
FATAL IF GIVEN
BY OTHER
ROUTES112,113
24 h F, RT122
- auxiliary label:
WARNING: FOR
INTRAVENOUS
USE ONLY
FATAL IF GIVEN
BY OTHER
ROUTES112,113
NS, D5W, NS,

D5NS, Ringers,
Ringers Lactate121
N/A122
10 mg/mL122
discard unused
portion122

0.5-2.0 mg/mL122
NS, D5W, NS,
D5NS, Ringers,
Ringers Lactate122
29/34
Zoledronic acid
(ZOMETA)
4 mg/5 mL
(Dr Reddys)
(RT)
no preservative123
Zoledronic acid
(ZOMETA)
4 mg/ 5 mL
(Novartis)
(RT)
no preservative124
N/A
0.8 mg/mL123
discard unused
portion123
100 mL NS, D5W123
complete infusion
within 24 h of
preparation123
Refrigerate diluted
product if not used
immediately after
preparation; bring to
RT prior to
administration123
N/A124
0.8 mg/ mL124
discard unused
portion2
100 mL NS, D5W124
complete infusion
within 24 h of
preparation124
Refrigerate diluted
product if not used
immediately after
preparation; bring to
RT prior to
administration124
* Suggested volume based on usual dose range and any concentration range of stability data
** Protect from light means minimizing exposure to direct sunlight over a storage period. More specific information on protection from light (eg, protecting container and tubing during
administration) will be indicated in the Under the Special Precautions/Notes column.
Centres are not to change the content locally but should forward suggestions to the Cancer Drug Manual staff.

30/34
Explanatory Notes
Stability data assumes products prepared using standard aseptic technique in biological safety cabinet at low risk for contamination according to the classification
30,125
outlined in USP 797.
Vial stability: Stability of solution after first puncture or reconstituted solution.
Storage temperature: If information states same stability with refrigerator and room temperature storage, then fridge stability is bolded as preferred (ie, to minimize
growth of micro-organisms).
Discard unused portion: Unused portion from single use vials should be discarded at the end of the day.
overfill known is stated if the manufacturer states overfill that is present is within acceptable limits.
Complete administration within __ is stated if the manufacturer specifies that the infusion must be completed in a specific time frame following preparation,
usually including entire time required for preparation (from first puncture), storage, and administration of infusion.
Abbreviations
BWI = bacteriostatic water for injection
CIVI: ambulatory pump = Continuous Intravenous Infusion (e.g., elastomeric infusor)
D5W = dextrose 5% in water
F = refrigerate
Non-DEHP = not containing Di(2-ethylhexyl) phthalate (DEHP)
NS = normal saline
PFL = protect from light
RT = room temperature
SWI = sterile water for injection
References
1. Hospira Healthcare Corporation. LEUCOVORIN CALCIUM INJECTION product monograph. Saint-Laurent, Quebec; 7 June 2007.
2. BC Cancer Agency. Pharmacy Policy Number II-20: Guiding Principles for Chemotherapy Preparation Chart. Vancouver, British Columbia: BC Cancer Agency; 19 September 2007.
3. John Korontzis. Personal communication. Regulatory Affairs Associate, Leucovorin Calcium, Mayne Pharma Canada; February 2005.
4. The United States Pharmacopeial Convention, Inc. General Chapter 797: Pharmaceutical compounding - sterile preparations. USP 27-NF 22. Rockville, Maryland: The United States Pharmacopeial
Convention, Inc.; 2003.
5. Teva Canada Limited. Leucovorin calcium injection product monograph. Toronto, Ontario; 5 May 2014.
6. Novopharm Limited (Teva). LEUCOVORIN CALCIUM Injection product information package. Toronto, Ontario; undated.
7. BC Cancer Agency. Pharmacy Policy Number II-20: Guiding Principles for Chemotherapy Preparation Chart. Vancouver, British Columbia: BC Cancer Agency; 6 January 2006.
8. Ovation Pharmaceuticals Inc. MUSTARGEN Package Insert. Deerfield, Illinois; October 2005.
9. Trissel LA. Handbook on Injectable Drugs. 13th ed. Bethesda, MD: American Society of Health-System Pharmacists, Inc.; 2005.
10. Trissel LA. Handbook on Injectable Drugs. 12th ed. Bethesda, MD: American Society of Health-System Pharmacists, Inc.; 2003.
11. GlaxoSmithKline Inc. Alkeran Package Insert. Mississauga, Ontario; Montreal, Quebec; 2004.
12. Pharmaceutical Partners of Canada Inc. Mesna Package Insert. Richmond Hill, Ontario; November 2001.
13. Mayne Pharma Canada. Methotrexate Product Monograph. Montreal, Quebec; December 2003.
14. John Korontzis. Personal communication. Regulatory Affairs Associate, Methotrexate, Mayne Pharma Canada; February 2005.
15. John Korontzis. Personal communication. Regulatory Affairs Associate, Fluorouracil, Methotrexate, Vincristine, Mayne Pharma Canada; 14 March 2005.

31/34
16. BC Cancer Agency Miscellaneous Origins Tumour Group. (MOHDMTX) BCCA Protocol Summary for Treatment of Meningeal Disease (Miscellaneous Tumour Origins) using High Dose
Methotrexate with Leucovorin Rescue. Vancouver, British Columbia: BC Cancer Agency; 1 Jan 2013.
17. BC Cancer Agency Sarcoma Tumour Group. (SAHDMTX) BCCA Protocol Summary for Treatment of Osteosarcoma Using High Dose Methotrexate with Leucovorin Rescue. Vancouver, British
Columbia: BC Cancer Agency; 1 Nov 2012.
18. BC Cancer Agency Lymphoma Tumour Group. (LYHDMRP) BCCA Protocol Summary for Treatment of Primary Intracerebral Lymphoma with High Dose Methotrexate and riTUXimab.
Vancouver, British Columbia: BC Cancer Agency; 1 Jun 2014.
19. BC Cancer Agency Lymphoma Tumour Group. (LYHDMTXP) BCCA Protocol Summary for Treatment of Primary Intracerebral Lymphoma with High Dose Methotrexate. Vancouver, British
Columbia: BC Cancer Agency; 1 Jun 2014.
20. BC Cancer Agency Lymphoma Tumour Group. (LYHDMTXR) BCCA Protocol Summary for Treatment of Leptomeningeal Lymphoma or Recurrent Intracerebral Lymphoma with High Dose
Methotrexate. Vancouver, British Columbia: BC Cancer Agency; 1 Jun 2014.
21. Hospira Healthcare Corporation. Methotrexate Injection USP product monograph. Saint-Laurent, Quebec; 27 June 2012.
22. Trissel's2 IV Compatibility (database on the Internet). Methotrexate sodium. Thomson Reuters MICROMEDEX 2.0, updated periodically. Available at: http://www.micromedex.com. Accessed 9
March 2015.
23. BC Cancer Agency. Pharmacy Policy Number III-50-02: Methotrexate Intrathecal Injection. Vancouver, British Columbia: BC Cancer Agency; 27 January 2006.
24. BC Cancer Agency Miscellaneous Origin Tumour Group. BCCA protocol summary for solid tumours using intrathecal methotrexate and/or thiptepa and/or cytarabine (MOIT). Vancouver, British
Columbia: BC Cancer Agency; 1 July 2005.
25. BC Cancer Agency. Systemic Therapy Policy III-50: Administration of Cytotoxic Drugs by the Intrathecal Route via Lumbar Puncture or Ommaya Reservoir. Vancouver, British Columbia; 31
October 2002.
26. Hospira Healthcare Corporation. Methotrexate Injection USP product monograph. Saint-Laurent, Quebec; 05 May 2009.
27. BC Cancer Agency. Pharmacy Policy Number II-20: Guiding Principles for Chemotherapy Preparation Chart. Vancouver, British Columbia: BC Cancer Agency; 19 September 2007.
28. Novopharm Limited. Mitomycin for Injection Product Monograph. Scarborough, Ontario; 23 December 1996.
29. Bristol Laboratories of Canada. Mutamycin Package Insert. Montreal, Canada; 2000.
30. The United States Pharmacopeia (USP). General Chapter 797: Pharmaceutical compounding - sterile preparations. USP 27-NF 22. Rockville, Maryland: The United States Pharmacopeial
Convention, Inc.; 2004.
31. Hospira Healthcare Corporation. Mitoxantrone Injection, USP Product Monograph. Saint-Laurent, Quebec; 13 June 2007.
32. Novopharm Limited. Mitoxantrone Injection Product Monograph. Toronto, Ontario; 19 May 2005.
33. Angie Chan. Personal communication. Drug Information Pharmacist, Novopharm; 7 Mar 2008.
34. Pharmaceutical Partners of Canada. Mitoxantrone Injection, USP Package Insert. Richmond Hill, Ontario; February 2007.
35. Bristol-Myers Squibb Canada. OPDIVO product monograph. Montreal, Quebec; 24 September 2015.
36. Hoffmann-La Roche Ltd. GAZYVA product monograph. Mississauga, Ontario; 21 December 2015.
37. Anna Sivojelezova MSc. Personal communication. Drug Information Associate; Hoffmann-La Roche Ltd Drug Information; 24 April 2015.
38. Omega Laboratories Ltd. Octreotide Acetate Injection product monograph. Montreal, Quebec; 23 July 2010.
39. Novopharm Limited. Octreotide Injection Product Monograph. Scarborough, Ontario; 15 March 2007.
40. Novartis Pharmaceuticals Canada Inc. SANDOSTATIN Product Monograph. Dorval, Quebec; 9 January 2001.
41. Repchinsky C, editor. Sandostatin LAR monograph, Compendium of Pharmaceuticals and Specialties. Ottawa, Ontario: Canadian Pharmacists Association; 2005. p. 1912-1916.
42. Repchinsky C editor. Compendium of Pharmaceuticals and Specialties. 12th ed. Ottawa, Ontario: Canadian Pharmacists Association; 2004.
43. Vancouver Hospital and Health Sciences Centre Pharmacy Department. Octreotide. Parenteral drug therapy manual. Vancouver, BC; February 2002.
44. GlaxoSmithKline. Guidance Booklet: compassionate use access of ofatumumab for patients with chronic lymphocytic leukemia (CLL) who are refractory to fludarabine and alemtuzumab or who are
deemed inappropriate for alemtuzumab therapy. version 5; 1 February 2010.
45. sanofi-aventis Canada Inc. ELOXATIN product monograph. Laval, Quebec; 13 January 2009.
46. Eiden C, Philibert L, Bekhtari K, et al. Physicochemical stability of oxaliplatin in 5% dextrose injection stored in polyvinyl chloride, polyethylene, and polypropylene infusion bags. Am J Health
Syst Pharm 2009;66.
47. Andre P, Cisternino S, Roy A-, et al. Stability of oxaliplatin in infusion bags containing 5% dextrose injection. American Journal of Health-System Pharmacy 2007;64(18):1950-1954.
48. Accord Healthcare Inc. Paclitaxel injection product monograph. Markham, Ontario; 13 August 2012.
49. Claude Mercure. Personal communication. Production Manager Biolyse Pharma Corporation; 21 December 2009.
50. Biolyse. PACLITAXEL FOR INJECTION product monograph. St. Catherines, Ontario; 2 December 2005.

32/34
51. Claude Mercure. Personal communication. Manager, Biolyse Pharma Corporation; 24 June 2014.
52. Zeng Z, Lazakovitch E. Study IR 120: Physical and Chemical Stability Study of Paclitaxel for Injection in 0.9 % Sodium Chloride in concentration range 0.012-0.12 mg/mL. Biolyse Pharma March
2010.
53. Mercure C. Stability of 0.1 mg/mL of paclitaxel for injection in sodium chloride (0.9%) solution. St Catharines, Ontario: Biolyse Pharma; 2 February 2007.
54. Xu Q, Trissel LA, Martinez JF. Stability of paclitaxel in 5% dextrose injection or 0.9% sodium chloride injection at 4, 22, or 32 degrees C. Am J Hosp Pharm 1994;51(24):3058-60.
55. Lisa Tavano. Personal communication. Biolyse Pharma Corporation; 14 May 2012.
56. Bristol-Myers Squibb Canada. TAXOL product monograph. Montreal, Ontario; 22 February 2010.
57. Robyn Mackenzie. Personal communication. Hospira Healthcare Corporation; 4 April 2012.
58. Hospira Healthcare Corporation. PACLITAXEL FOR INJECTION product monograph. Saint-Laurent, Quebec; 1 September 2009.
59. Rose Toussaint. Personal communication. Hospira Canada Healthcare Corporation; 4 April 2012.
60. Celgene Inc. ABRAXANE product monograph. Mississauga, Ontario; 24 July 2014.
61. Aisling Cahill. Drug Safety and Medical Information Specialist. Personal communication. Celgene Inc.; 23 April 2015.
62. Mayne Pharma (Canada) Inc. Pamidronate Package Insert. Montreal, Quebec; 2002.
63. BC Cancer Agency Breast Tumour Group. BCCA protocol summary for treatment of acute bone pain secondary to breast cancer metastases using pamidronate or IV clodronate (BRAVPAM).
Vancouver, British Columbia: BC Cancer Agency; 1 May 2001.
64. Omega Laboratories Ltd. Pamidronate Disodium product monograph. Montreal, Quebec; 06 June 2005.
65. Pharmaceutical Partners of Canada. Pamidronate Disodium For Injection product monograph. Richmond Hill, Ontario; 18 January 2010.
66. Sandoz Canada Inc. Pamidronate injection product monograph. Boucherville, Quebec; 28 February 2006.
67. Amgen Canada. VECTIBIX product monograph. Mississauga, Ontario; 5 March 2009.
68. Diane Lord. Personal communication. Amgen Canada Inc Medical Information Department; 19 June 2009.
69. sigma-tau Pharmaceuticals Inc. ONCASPAR prescribing information. Gaithersburg, Maryland USA; May 2014.
70. Merck Canada Inc. KEYTRUDA product monograph. Kirkland, Quebec; 5 February 2016.
71. Eli Lilly Canada. Pemetrexed product information. Toronto, Ontario; 2008.
72. Eli Lilly Canada Inc. ALIMTA Product Monograph. Toronto, Ontario; 21 May 2004.
73. Hoffmann-La Roche Limited. PERJETA product monograph. Mississauga, Ontario; 12 April 2013.
74. Axcan Pharma Inc. Photofrin Package Insert. Mont-Saint-Hilaire, Quebec; 2004.
75. Marie-Helene Doyon B.Pharm. M.Sc. Personal communication. Medical Information Specialist, Porfimer, Axcan Pharma. 3 March 2005.
76. Hospira Healthcare Corporation. TOMUDEX product monograph. Saint-Laurent, Quebec; 23 April 2008.
77. Eli Lilly Canada Inc. CYRAMZA product monograph. Toronto, Ontario; 16 July 2015.
78. Oncolytics Biotech Inc. Pharmacy Manual Protocol REO 018: Randomized, double-blind, multicentre two-stage adaptive phase 3 study of intravenous administration of blinded REOLYSIN
(Reovirus Type 3 - Dearing) in combination with paclitaxel and carboplatin versus the chemotherapy alone in patients with metastatic or recurrent squamous cell carcinoma of the head and neck who
have progressed on or after prior platinum-based chemotherapy. 15 February 2011 - version 5.0 (North America).
79. Hoffmann-La Roche Ltd. RITUXAN product monograph. Mississauga, Ontario; 29 March 2012.
80. Hoffmann-La Roche Ltd. RITUXAN product monograph. Mississauga, Ontario; 29 May 2014.
81. Diana Fung pharmacist. Personal communication. Hoffmann-La Roche Medical Information; 16 July 2014.
82. Celgene Inc Medical Information. Compatibility and stability of ISTODAX (romidepsin) for Injection with intravenous solutions. Mississauga, Ontario; v2.2CAN; 13 September 2013.
83. Celgene Inc Medical Information. Preparation and administration of ISTODAX (romidepsin) for Injection. Mississauga, Ontario; v5.2CAN; 13 September 2013.
84. Janssen Inc. SYLVANT product monograph. Toronto, Ontario; 6 January 2016.
85. Pharmacia Canada Inc. Zanosar Package Insert. Mississauga, Ontario; March 2003.
86. Schering-Plough Canada. TEMODAL product monograph. Kirkland, Quebec; 5 January 2009.
87. Wyeth Canada. TORISEL product monograph. Montreal, Canada; 16 October 2008.
88. McEvoy GK, editor. AHFS 2008 Drug Information. Bethesda, Maryland: American Society of Health-System Pharmacists, Inc. p. 1226-1228.
89. Anna Sivojelezova M.Sc. Personal communication. Medical Information Associate, Wyeth. 6 January 2010.
90. Bristol-Myers Squibb Canada. VUMON product monograph. St. Laurent, Quebec; 26 October 2004.
91. Trissel's2 IV Compatibility (database on the Internet). Teniposide. Thomson Reuters MICROMEDEX 2.0, updated periodically. Available at: http://www.micromedex.com. Accessed 27 April
2011.

33/34
92. Bedford Laboratories. Thiotepa for Injection USP Package Insert. Bedford, Ohio; April 2001.
93. Solimando D.A. Updates of melphalan and thiotepa. Hosp Pharm 1997;32(8):1082-1088.
94. Christina Hsu Pharm. D. Personal communication. Bedford Laboratories Professional Services Department; 29 August 2008.
95. Trissel LA. Handbook on Injectable Drugs. 13th ed. Bethesda, Maryland: American Society of Health-System Pharmacists, Inc.; 2005. p. 1395-1403.
96. BC Cancer Agency Miscellaneous Origin Tumour Group. (MOIT) BCCA Protocol Summary for Soild Tumours using Intrathecal Methotrexate and/or Thiotepa and/or Cytarabine. Vancouver,
British Columbia: BC Cancer Agency; 1 July 2005.
97. Genzyme Canada. Thyrogen Product Monograph. Mississauga, Ontario; 2004.
98. Genentech Inc. ACTEMRA product information. South San Francisco, California; January 2010.
99. Hoffmann-La Roche Ltd. Provision of tocilizumab for a patient with multicentric Castleman's Disease: guidelines for compassionate use. May 2010.
100. Hospira Healthcare. Topotecan Hydrochloride for Injection product monograph. Saint-Laurent, QC; 22 June 2012.
101. Hospira Healthcare Corporation. Topotecan hydrochloride for injection product monograph. Saint-Laurent, Quebec; 26 August 2014.
102. Mylan Pharmaceuticals ULC. Topotecan hydrochloride for injection product monograph. Etobicoke, Ontario; 18 February 2015.
103. Sandoz Canada Inc. Topotecan injection product monograph. Boucherville, Quebec; 5 September 2014.
104. Hoffman-La Roche Limited. HERCEPTIN product monograph. Mississauga, Ontario; 16 November 2012.
105. Hoffmann-La Roche Limited. KADCYLA product monograph. Mississauga, Ontario; 11 September 2013.
106. medac UK. TREOSULFAN injection product monograph. Hamburg, Germany; 24 June 2008.
107. Henrik Fenger. Personal communication. Management Assiciate, International Division medac; 03 March 2010.
108. Mayne Pharma (Canada) Inc. Vinblastine product monograph. Kirkland, Quebec; 10 August 2003.
109. Lexi-Drugs (database on the Internet). VinBLAStine. Lexi-Comp Inc., 3 November 2014. Available at: http://online.lexi.com. Accessed 20 November 2014.
110. Jan Barrow. Personal communication. Supervisor, Hospira Canada Clinical Support. Saint-Laurent, Quebec; 03 December 2007.
111. Tanya Leduc. Personal communication. Acting editor, BC Cancer Agency Cancer Drug Manual; 18 Dec 2007.
112. World Health Organization. Information Exchange System: Alert No. 115 (QSM/MC/IEA.115). Geneva, Switzerland: World Health Organization; 18 July 2007.
113. BCCA Provincial Systemic Therapy Program. Labeling of vinca alkaloid syringes. Policy # V-40. Vancouver, British Columbia: BC Cancer Agency; 27 May 1999.
114. Teva Canada Limited. Vinblastine sulfate injection product monograph. Toronto, Ontario; 1 February 2013.
115. Trissel's2 IV Compatibility (database on the Internet). Vinblastine sulfate. Thomson Reuters MICROMEDEX 2.0, updated periodically. Available at: http://www.micromedex.com. Accessed 8
June 2015.
116. Mayne Pharma (Canada) Inc. Vincristine Package Insert. Montreal, QC; Undated.
117. Teva Canada Limited. Vincristine sulfate injection product monograph. Scarborough, Ontario; 27 March 2014.
118. Lexi-Drugs (database on the Internet). VinCRIStine. Lexi-Comp Inc., 3 June 2015. Available at: http://online.lexi.com. Accessed 9 June 2015.
119. GlaxoSmithKline Inc. Navelbine Package Insert. Mississauga, Ontario; Montreal, Quebec; Undated.
120. Mayne Pharma (Canada) Inc. Vinorelbine Product Monograph. Montreal, QC; Undated.
121. Pharmaceutical Partners of Canada. Vinorelbine Injection product monograph. Richmond Hill, Ontario; 15 January 2008.
122. Pierre Fabre Pharma Canada Inc. Vinorelbine injection package insert. St Bruno de Montarville, Quebec; undated.
123. Innomar Strategies Inc. (for Dr. Reddy's Laboratories Limited). Zoledronic acid for injection concentrate product monograph. Oakville, Ontario; 11 March 2015.
124. Novartis Pharmaceuticals Canada Inc. ZOMETA product monograph. Dorval, Quebec; 26 July 2013.
125. Kastango ES. The ASHP discussion guide for compounding sterile preparations. Bethesda (MD): American Society of Health-System Pharmacists, Inc.; 2004. p. 5.

34/34

Chemo Stability Chart LtoZ

Încărcat de

Informații document

Drepturi de autor

Formate disponibile

Partajați acest document

Partajați sau inserați document

Opțiuni de partajare

Vi se pare util acest document?

Este necorespunzător acest conținut?

Drepturi de autor:

Formate disponibile

Chemo Stability Chart LtoZ

Încărcat de

Drepturi de autor:

Formate disponibile

BC CANCER AGENCY CHEMOTHERAPY PREPARATION AND STABILITY CHART

DRUG & STRENGTH

(e.g., 50-250 mL*)

BC Cancer Agency Chemotherapy Preparation and Stability Chart version 2.00

BC CANCER AGENCY CHEMOTHERAPY PREPARATION AND STABILITY CHART

0.06-1 mg/mL NS,

(e.g., 50-250 mL*)

BC Cancer Agency Chemotherapy Preparation and Stability Chart version 2.00

BC CANCER AGENCY CHEMOTHERAPY PREPARATION AND STABILITY CHART

0.1 0.45 mg/mL in

(e.g., greater than 45

BC Cancer Agency Chemotherapy Preparation and Stability Chart version 2.00

BC CANCER AGENCY CHEMOTHERAPY PREPARATION AND STABILITY CHART

Greater than or equal

high dose (e.g., 1-12

use within 4 h of initial

BC Cancer Agency Chemotherapy Preparation and Stability Chart version 2.00

BC CANCER AGENCY CHEMOTHERAPY PREPARATION AND STABILITY CHART

100 mL* NS, D5W13

NS, D5W, sodium

BC Cancer Agency Chemotherapy Preparation and Stability Chart version 2.00

BC CANCER AGENCY CHEMOTHERAPY PREPARATION AND STABILITY CHART

Greater than or equal

BC Cancer Agency Chemotherapy Preparation and Stability Chart version 2.00

Greater than or equal

Greater than or equal

BC CANCER AGENCY CHEMOTHERAPY PREPARATION AND STABILITY CHART

BC Cancer Agency Chemotherapy Preparation and Stability Chart version 2.00

BC CANCER AGENCY CHEMOTHERAPY PREPARATION AND STABILITY CHART

Use within 4 h38

single use vials: use

BC Cancer Agency Chemotherapy Preparation and Stability Chart version 2.00

single use or multidose

BC CANCER AGENCY CHEMOTHERAPY PREPARATION AND STABILITY CHART

use within 4 h of initial

BC Cancer Agency Chemotherapy Preparation and Stability Chart version 2.00

BC CANCER AGENCY CHEMOTHERAPY PREPARATION AND STABILITY CHART

BC Cancer Agency Chemotherapy Preparation and Stability Chart version 2.00

BC CANCER AGENCY CHEMOTHERAPY PREPARATION AND STABILITY CHART

BC Cancer Agency Chemotherapy Preparation and Stability Chart version 2.00

0.3-1.2 mg/mL in NS,

devices with spikes

BC CANCER AGENCY CHEMOTHERAPY PREPARATION AND STABILITY CHART

0.3-1.2 mg/mL in NS,

0.1 mg/mL in NS53

devices with spikes

BC Cancer Agency Chemotherapy Preparation and Stability Chart version 2.00

BC CANCER AGENCY CHEMOTHERAPY PREPARATION AND STABILITY CHART

0.3-1.2 mg/mL in NS,

0.1-1 mg/mL in NS,

devices with spikes

BC Cancer Agency Chemotherapy Preparation and Stability Chart version 2.00

0.3-1.2 mg/mL in NS,

devices with spikes

BC CANCER AGENCY CHEMOTHERAPY PREPARATION AND STABILITY CHART

in empty sterile PVC,

- each vial contains

0.060.36 mg/mL NS,

- do NOT mix with

- let stand for

BC Cancer Agency Chemotherapy Preparation and Stability Chart version 2.00

e.g., 250 mL* NS

BC CANCER AGENCY CHEMOTHERAPY PREPARATION AND STABILITY CHART

0.060.36 mg/mL NS,